Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Convertible Debt (2016 - 2019)

Ani Pharmaceuticals' Convertible Debt history spans 9 years, with the latest figure at $117.6 million for Q3 2019.

  • On a quarterly basis, Convertible Debt fell 12.33% to $117.6 million in Q3 2019 year-over-year; TTM through Sep 2019 was $117.6 million, a 12.33% decrease, with the full-year FY2018 number at $112.5 million, down 12.28% from a year prior.
  • Convertible Debt hit $117.6 million in Q3 2019 for Ani Pharmaceuticals, up from $115.9 million in the prior quarter.
  • Over the last five years, Convertible Debt for ANIP hit a ceiling of $134.1 million in Q3 2018 and a floor of $112.2 million in Q1 2015.
  • Historically, Convertible Debt has averaged $120.2 million across 5 years, with a median of $117.6 million in 2019.
  • Biggest five-year swings in Convertible Debt: grew 6.46% in 2015 and later decreased 12.33% in 2019.
  • Tracing ANIP's Convertible Debt over 5 years: stood at $113.4 million in 2015, then increased by 6.36% to $120.6 million in 2016, then rose by 6.27% to $128.2 million in 2017, then decreased by 12.28% to $112.5 million in 2018, then rose by 4.56% to $117.6 million in 2019.
  • Business Quant data shows Convertible Debt for ANIP at $117.6 million in Q3 2019, $115.9 million in Q2 2019, and $114.2 million in Q1 2019.